Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of BioScrip, Inc. Stockholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ:BIOS) concerning the Company’s alleged participation in a kickback scheme.

A U.S. Department of Justice press release issued on January 8, 2014 revealed that BioScrip agreed to forfeit $15 million for the Company’s alleged participation in a kickback scheme with Novartis Pharmaceuticals Corporation related to Novartis’s product Exjade®. Furthermore, on March 31, 2015, a federal judge denied, in part, a motion to dismiss a complaint alleging that BioScrip made misleading statements pertaining to the distribution of Exjade®.

If you are a BioScrip stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at [e-mail], or telephone at [phone], Melissa Fortunato, Esq. by email at [e-mail], or telephone at [phone], or toll free at [phone], or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

Kirby McInerney LLPJ. Brandon Walker, Esq., (212) [e-mail] Fortunato, Esq., (212) [e-mail]